Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.55 |
| ▸ | EGFR | P00533 | 7/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.53 |
| ▸ | KRAS | P01116 | 3/20 | 0.52 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23360651 | 1.00 | PIK3CD (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGEGFR | |
| SCHEMBL23360348 | 0.87 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGERBB2 | |
| SCHEMBL23360352 | 0.87 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGERBB2 | |
| SCHEMBL28834247 | 0.86 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGEGFR | |
| SCHEMBL28834249 | 0.86 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGEGFR | |
| SCHEMBL29933502 | 0.86 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGEGFR | |
| SCHEMBL25130494 | 0.77 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGEGFR | |
| SCHEMBL3129523 | 0.77 | EGFR (0.56) | EGFRERBB2 | |
| SCHEMBL4087511 | 0.77 | EGFR (0.56) | EGFRERBB2 | |
| SCHEMBL4091279 | 0.77 | EGFR (0.52) | EGFRERBB2PDE10APDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| CN-114867719-A | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2022-08-05 | — | — | CN | disclosed |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | PIK3CD 641/4885PIK3CA 440/4885PIK3CB 927/4885 |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | FAP, APC, VHL | PIK3CD 641/4885PIK3CA 440/4885PIK3CB 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.